A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study of Rucaparib in combination with Nivolumab versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancer
Brief description of study
If you have been newly diagnosed with high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer that has responded to chemotherapy, you may qualify for this study. The main goal of this study is to see how your cancer responds to the study treatment of rucaparib and/or nivolumab
Clinical Study Identifier: s17-01523
ClinicalTrials.gov Identifier: NCTs17-01523
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
